US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jul 2, 2013 (13 years ago)

traZODone HCl Tablet

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mixup; traZODone HCl Tablet, 50 mg may be potentially mislabeled as AMANTADINE HCL, Tablet, 100 mg, NDC 00832011100, Pedigree: AD54475_1, EXP: 5/20/2014.

What was recalled

traZODone HCl Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 50111043303

Recalling firm
Aidapak Services, LLC
Origin
WA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-593-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Trazodone recalls

See all
Class II · Moderate risk Ongoing

Trazodone Hydrochloride

Reason Presence of Foreign Tablets/Capsules

Granules Pharmaceuticals Inc. NDC 70010-231-01 D-0305-2026
Class III · Low risk Ongoing

traZODONE Hydrochloride Tablets

Reason Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.

Zydus Pharmaceuticals (USA) Inc NDC 68382-806-10 D-0247-2026
Class II · Moderate risk Terminated

Trazodone Hydrochloride Tablets

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. D-0510-2021
Class I · High risk Terminated

TraZODONE Hydrochloride Tablets USP 100 mg

Reason Product mix-up: Bottles of sildenafil and trazodone were inadvertently packaged together during bottling at a 3rd party facility.

AVKARE Inc. NDC 42291-834-10 D-0168-2021
Class II · Moderate risk Terminated

Trazodone HCl active pharmaceutical ingredient packaged in…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-940-2015